<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02549040</url>
  </required_header>
  <id_info>
    <org_study_id>1439-046</org_study_id>
    <secondary_id>2015-002702-36</secondary_id>
    <secondary_id>MK-1439-046</secondary_id>
    <nct_id>NCT02549040</nct_id>
  </id_info>
  <brief_title>Bioavailability of MK-1439 Experimental Nano Formulations in Healthy Adults (MK-1439-046)</brief_title>
  <official_title>A Rapid Pharmacokinetic Trial of the Bioavailability of Four MK-1439 Nano Formulations in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate and compare the relative bioavailability of different MK-1439
      experimental nano formulations (NFs) with that of a MK-1439 film coated tablet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2015</start_date>
  <completion_date type="Actual">December 24, 2015</completion_date>
  <primary_completion_date type="Actual">December 24, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-1439</measure>
    <time_frame>Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose</time_frame>
    <description>During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-inf after a single administration of MK-1439.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to Last Time (AUC0-last) With Quantifiable MK-1439 Following a Single Administration of MK-1439</measure>
    <time_frame>Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose</time_frame>
    <description>During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-last after a single administration of MK-1439.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of MK-1439 Following a Single Administration of MK-1439</measure>
    <time_frame>Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose</time_frame>
    <description>During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose to determine Cmax after a single administration of MK-1439.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of MK-1439 at 24 Hours Post-dose (C24hr) Following a Single Administration of MK-1439</measure>
    <time_frame>Periods 1 to 5: 24 hours post-dose</time_frame>
    <description>During each of the 5 treatment periods, blood samples were collected 24 hours after dosing to determine C24hr after a single administration of MK-1439.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced at Least One Adverse Event</measure>
    <time_frame>Up to 16 days after last dose of study treatment (up to approximately 92 days)</time_frame>
    <description>An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due to an Adverse Event</measure>
    <time_frame>Up to 4 days after last dose of study treatment (up to approximately 76 days)</time_frame>
    <description>An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours (AUC0-48 hr) Post-dose of MK-1439 Following a Single Administration of MK-1439</measure>
    <time_frame>Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours post-dose</time_frame>
    <description>During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48 hours after dosing to determine AUC0-48hr after a single administration of MK-1439.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Human Immunodeficiency Virus-1 (HIV-1)</condition>
  <arm_group>
    <arm_group_label>MK-1439 fixed sequence treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]). During Period 2, participants received Treatment A: MK-1439 100 mg film coated tablet. During Period 3, participants received Treatment C: MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]). During Period 4, participants received Treatment D: MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]. During Period 5, participants received Treatment E: MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]). Each period was separated by a 14 day washout.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A: MK-1439 100 mg film coated tablet</intervention_name>
    <description>Single MK-1439 100 mg film coated tablet administered orally at the start of Period 2</description>
    <arm_group_label>MK-1439 fixed sequence treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B: MK-1439 150 mg tablet (40% drug loaded granule)</intervention_name>
    <description>Single MK-1439 NF Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1</description>
    <arm_group_label>MK-1439 fixed sequence treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C: MK-1439 150 mg tablet (30% drug loaded granule)</intervention_name>
    <description>Single MK-1439 NF Type 2 dose (150 mg tablet [30% drug loaded granule])administered orally at the start of Period 3</description>
    <arm_group_label>MK-1439 fixed sequence treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment D: MK-1439 150 mg tablet (50% drug loaded granule)</intervention_name>
    <description>Single MK-1439 NF Type 3 dose (150 mg tablet [50% drug loaded granule])administered orally at the start of Period 4</description>
    <arm_group_label>MK-1439 fixed sequence treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment E: MK-1439 100 mg tablet (30% drug loaded granule)</intervention_name>
    <description>Single MK-1439 NF Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5</description>
    <arm_group_label>MK-1439 fixed sequence treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy participants

          -  have been a non-smoker and/or have not used nicotine or nicotine-containing products
             for at least approximately 3 months

        Exclusion Criteria:

          -  is a pregnant or a nursing female

          -  has a history of stroke, chronic seizures or major neurological disorder

          -  has a history of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, hepatic, immunological, renal, respiratory, or genitourinary
             abnormalities or diseases

          -  has a history of neoplastic disease (including leukemia, lymphoma, malignant
             melanoma), or myeloproliferative disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2015</study_first_posted>
  <results_first_submitted>September 27, 2018</results_first_submitted>
  <results_first_submitted_qc>February 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 22, 2019</results_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MK-1439 Fixed Sequence Treatment</title>
          <description>After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]). During Period 2, participants received Treatment A: MK-1439 100 mg film coated tablet. During Period 3, participants received Treatment C: MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]). During Period 4, participants received Treatment D: MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]. During Period 5, participants received Treatment E: MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]). Each period was separated by a 14 day washout.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK-1439 Fixed Sequence Treatment</title>
          <description>After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]). During Period 2, participants received Treatment A: MK-1439 100 mg film coated tablet. During Period 3, participants received Treatment C: MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]). During Period 4, participants received Treatment D: MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]. During Period 5, participants received Treatment E: MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]). Each period was separated by a 14 day washout.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.8" spread="9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-1439</title>
        <description>During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-inf after a single administration of MK-1439.</description>
        <time_frame>Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose</time_frame>
        <population>Participants who complied with the protocol sufficiently to ensure that the data exhibited the effects of treatment, according to the underlying scientific model. Participants were excluded from descriptive statistics for AUC0-inf if there were insufficient data in the terminal phase to characterize half-life (t1/2).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: MK-1439 100 mg Film Coated Tablet</title>
            <description>Participants received a single MK-1439 100 mg film coated tablet administered orally at the start of Period 2</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]) administered orally at the start of Period 3</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]) administered orally at the start of Period 4</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1439 Following a Single Administration of MK-1439</title>
          <description>During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-inf after a single administration of MK-1439.</description>
          <population>Participants who complied with the protocol sufficiently to ensure that the data exhibited the effects of treatment, according to the underlying scientific model. Participants were excluded from descriptive statistics for AUC0-inf if there were insufficient data in the terminal phase to characterize half-life (t1/2).</population>
          <units>µM*h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="34.6"/>
                    <measurement group_id="O2" value="31.9" spread="33.9"/>
                    <measurement group_id="O3" value="35.5" spread="29.6"/>
                    <measurement group_id="O4" value="29.1" spread="30.3"/>
                    <measurement group_id="O5" value="28.0" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment B: MK-1439 150 mg tablet (40% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment C: MK-1439 150 mg tablet (30% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment D: MK-1439 150 mg tablet (50% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment E: MK-1439 100 mg tablet (30% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.89</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to Last Time (AUC0-last) With Quantifiable MK-1439 Following a Single Administration of MK-1439</title>
        <description>During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-last after a single administration of MK-1439.</description>
        <time_frame>Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose</time_frame>
        <population>Participants who complied with the protocol sufficiently to ensure that the data exhibited the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: MK-1439 100 mg Film Coated Tablet</title>
            <description>Participants received a single MK-1439 100 mg film coated tablet administered orally at the start of Period 2</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]) administered orally at the start of Period 3</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]) administered orally at the start of Period 4</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to Last Time (AUC0-last) With Quantifiable MK-1439 Following a Single Administration of MK-1439</title>
          <description>During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose to determine AUC0-last after a single administration of MK-1439.</description>
          <population>Participants who complied with the protocol sufficiently to ensure that the data exhibited the effects of treatment, according to the underlying scientific model.</population>
          <units>μM*h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="29.3"/>
                    <measurement group_id="O2" value="29.9" spread="31.1"/>
                    <measurement group_id="O3" value="32.7" spread="26.3"/>
                    <measurement group_id="O4" value="27.0" spread="28.4"/>
                    <measurement group_id="O5" value="26.3" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment B: MK-1439 150 mg tablet (40% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment C: MK-1439 150 mg tablet (30% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.09</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment D: MK-1439 150 mg tablet (50% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment E: MK-1439 100 mg tablet (30% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of MK-1439 Following a Single Administration of MK-1439</title>
        <description>During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose to determine Cmax after a single administration of MK-1439.</description>
        <time_frame>Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48, and 72 hours post-dose</time_frame>
        <population>Participants who complied with the protocol sufficiently to ensure that the data exhibited the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: MK-1439 100 mg Film Coated Tablet</title>
            <description>Participants received a single MK-1439 100 mg film coated tablet administered orally at the start of Period 2</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]) administered orally at the start of Period 3</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]) administered orally at the start of Period 4</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of MK-1439 Following a Single Administration of MK-1439</title>
          <description>During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours post-dose to determine Cmax after a single administration of MK-1439.</description>
          <population>Participants who complied with the protocol sufficiently to ensure that the data exhibited the effects of treatment, according to the underlying scientific model.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1070" spread="26.5"/>
                    <measurement group_id="O2" value="1520" spread="32.5"/>
                    <measurement group_id="O3" value="1320" spread="27.8"/>
                    <measurement group_id="O4" value="1060" spread="27.0"/>
                    <measurement group_id="O5" value="1160" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment B: MK-1439 150 mg tablet (40% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment C: MK-1439 150 mg tablet (30% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment D: MK-1439 150 mg tablet (50% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment E: MK-1439 100 mg tablet (30% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.76</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration of MK-1439 at 24 Hours Post-dose (C24hr) Following a Single Administration of MK-1439</title>
        <description>During each of the 5 treatment periods, blood samples were collected 24 hours after dosing to determine C24hr after a single administration of MK-1439.</description>
        <time_frame>Periods 1 to 5: 24 hours post-dose</time_frame>
        <population>Participants who complied with the protocol sufficiently to ensure that the data exhibited the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: MK-1439 100 mg Film Coated Tablet</title>
            <description>Participants received a single MK-1439 100 mg film coated tablet administered orally at the start of Period 2</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]) administered orally at the start of Period 3</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]) administered orally at the start of Period 4</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of MK-1439 at 24 Hours Post-dose (C24hr) Following a Single Administration of MK-1439</title>
          <description>During each of the 5 treatment periods, blood samples were collected 24 hours after dosing to determine C24hr after a single administration of MK-1439.</description>
          <population>Participants who complied with the protocol sufficiently to ensure that the data exhibited the effects of treatment, according to the underlying scientific model.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395" spread="31.9"/>
                    <measurement group_id="O2" value="483" spread="33.3"/>
                    <measurement group_id="O3" value="508" spread="23.2"/>
                    <measurement group_id="O4" value="412" spread="28.0"/>
                    <measurement group_id="O5" value="402" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment B: MK-1439 150 mg tablet (40% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment C: MK-1439 150 mg tablet (30% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment D: MK-1439 150 mg tablet (50% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment E: MK-1439 100 mg tablet (30% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced at Least One Adverse Event</title>
        <description>An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.</description>
        <time_frame>Up to 16 days after last dose of study treatment (up to approximately 92 days)</time_frame>
        <population>All participants who received at least 1 administration of the trial drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: MK-1439 100 mg Film Coated Tablet</title>
            <description>Participants received a single MK-1439 100 mg film coated tablet administered orally at the start of Period 2</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]) administered orally at the start of Period 3</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]) administered orally at the start of Period 4</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced at Least One Adverse Event</title>
          <description>An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.</description>
          <population>All participants who received at least 1 administration of the trial drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Study Treatment Due to an Adverse Event</title>
        <description>An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.</description>
        <time_frame>Up to 4 days after last dose of study treatment (up to approximately 76 days)</time_frame>
        <population>All participants who received at least 1 administration of the trial drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: MK-1439 100 mg Film Coated Tablet</title>
            <description>Participants received a single MK-1439 100 mg film coated tablet administered orally at the start of Period 2</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]) administered orally at the start of Period 3</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]) administered orally at the start of Period 4</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Treatment Due to an Adverse Event</title>
          <description>An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study drug, whether or not it is considered related to the study drug.</description>
          <population>All participants who received at least 1 administration of the trial drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours (AUC0-48 hr) Post-dose of MK-1439 Following a Single Administration of MK-1439</title>
        <description>During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48 hours after dosing to determine AUC0-48hr after a single administration of MK-1439.</description>
        <time_frame>Periods 1 to 5 at the following time points: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, and 48 hours post-dose</time_frame>
        <population>Participants who complied with the protocol sufficiently to ensure that the data exhibited the effects of treatment, according to the underlying scientific model.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1</description>
          </group>
          <group group_id="O2">
            <title>Treatment A: MK-1439 100 mg Film Coated Tablet</title>
            <description>Participants received a single MK-1439 100 mg film coated tablet administered orally at the start of Period 2</description>
          </group>
          <group group_id="O3">
            <title>Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]) administered orally at the start of Period 3</description>
          </group>
          <group group_id="O4">
            <title>Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]) administered orally at the start of Period 4</description>
          </group>
          <group group_id="O5">
            <title>Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)</title>
            <description>Participants received a single MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours (AUC0-48 hr) Post-dose of MK-1439 Following a Single Administration of MK-1439</title>
          <description>During each of the 5 treatment periods, blood samples were collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24, 48 hours after dosing to determine AUC0-48hr after a single administration of MK-1439.</description>
          <population>Participants who complied with the protocol sufficiently to ensure that the data exhibited the effects of treatment, according to the underlying scientific model.</population>
          <units>µM*h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="27.5"/>
                    <measurement group_id="O2" value="27.2" spread="29.2"/>
                    <measurement group_id="O3" value="28.8" spread="24.8"/>
                    <measurement group_id="O4" value="23.2" spread="27.3"/>
                    <measurement group_id="O5" value="23.3" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment B: MK-1439 150 mg tablet (40% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment C: MK-1439 150 mg tablet (30% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment D: MK-1439 150 mg tablet (50% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.85</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Comparison of Treatment E: MK-1439 100 mg tablet (30% drug loaded granule) vs. Treatment A: MK-1439 100 mg film coated tablet</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric mean ratio</param_type>
            <param_value>0.86</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 16 days following the last dose of study treatment (up to approximately 92 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment B: MK-1439 150 mg Tablet (40% Drug Loaded Granule)</title>
          <description>Participants received a single MK-1439 Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1</description>
        </group>
        <group group_id="E2">
          <title>Treatment A: MK-1439 100 mg Film Coated Tablet</title>
          <description>Participants received a single MK-1439 100 mg film coated tablet administered orally at the start of Period 2</description>
        </group>
        <group group_id="E3">
          <title>Treatment C: MK-1439 150 mg Tablet (30% Drug Loaded Granule)</title>
          <description>Participants received a single MK-1439 Type 2 dose (150 mg tablet [30% drug loaded granule]) administered orally at the start of Period 3</description>
        </group>
        <group group_id="E4">
          <title>Treatment D: MK-1439 150 mg Tablet (50% Drug Loaded Granule)</title>
          <description>Participants received a single MK-1439 Type 3 dose (150 mg tablet [50% drug loaded granule]) administered orally at the start of Period 4</description>
        </group>
        <group group_id="E5">
          <title>Treatment E: MK-1439 100 mg Tablet (30% Drug Loaded Granule)</title>
          <description>Participants received a single MK-1439 Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling of body temperture change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Menstrual discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

